by Raynovich Rod | Aug 25, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
8/28/25 UPDATE-1 A small cap rally has helped SMID biotechs stabilize to some degree with the IWM up 5.4% over one month and 7.04% YTD but the anticipated big rally in general small caps has not yet developed.For example the ARKG is seriously lagging down over 3% MTD...
by Raynovich Rod | Jul 21, 2025 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 7/23/25…10:45 a BIOTECH rally continues with ARKG and XBI up on a GREEN SCREEN DAY: Finally — one of our new Trading LIST picks XENCOR (XNCR) shows Momentum at $9.80, undervalued with P/CASh. at 1.5,RSI is now soaring.,one new partnership will...
by Raynovich Rod | Aug 29, 2023 | 2024-25 Life Science Portfolios
Update-1 9/2 Biotechs nudge off bottom with IBB at 3 month high at $130 level. FTC concedes Amgen fight over Horizon deal. XBI finds an uptick of 2.44% to $81 handle on Friday. MedTech still sluggish with IHI in low fifties in choppy trading all year. Novartis joins...
by Rod Raynovich | Nov 21, 2022 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1 11/22 Broad Market Rally with all major indices up over 1%. Small cap spec stocks gain momentum, XBI up 1.38%. Energy materials and tech strong. IBB up 0.79% to $134. Bears acknowledge year end strength but still say 2023 fraught with weakening economy and...
by Raynovich Rod | Aug 30, 2021 | 2024-25 Life Science Portfolios
Update-1 3:45P 9/1 FDA issues warning on JAK Inhibitor drug class. ABBV down 7%., PFE and LLY drugs also affected. Small cap rally intact: CRSP,CYRX, VCYT. Quidel (QDEL) up 5.45% on need for more COVID tests. ARKG and XBI up about 1.5%. Mid-caps all green. IBB up...
by Raynovich Rod | Jun 9, 2021 | 2025 Rayno Biopharmaceuticals Portfolio
Update 6/14 2p -EDT The ASCO Rally tailwind looks good whether you are a trader or long term investor. As we called it on May 31 we thought the timing was right to add positions to biotech stocks. The rally is a bit more spotty now after a ~10% + move in the XBI but...
by Raynovich Rod | Jan 13, 2021 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
JPMorgan Healthcare Conference Notes #1: Current Portfolio Positions Focus is Coronavirus diagnostics and vaccines. Gene therapy is poised for next wave: The Conference boosted many stocks as you might expect in a bull market for biotech. We reviewed rather quickly...
by Raynovich Rod | Nov 4, 2019 | Biopharmaceuticals
Update-1 11/5 2p EST IBB flat, NAZ up 0.185, earnings from AMRN and REGN. Amarin down 3.5% to $16.83 on earnings but bulls are waiting for label expansion. Q3 Revenues are $112.4 M up 103%, increased prescriptions for Vascepa with a 12/28/19 PADUFA date. Regeneron...
by Raynovich Rod | Sep 18, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 A bit of a sell-off on end of week option expirations and cancellation of China visit to farm Bureau in MT. NAZ down 0.8%, S&P down 0.5%. Less reaction to China news now? Can biotech rally as contrian play to tech and industrials? tape in biotech was...
by Raynovich Rod | Apr 29, 2019 | Biopharmaceuticals
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma...
